In a prostate cancer model, Xu et al. (2019) tested combinatorial AREG blockade with chemotherapy, which demonstrated superior anti-tumor efficacy, even compared to co-treatment with the EGFR mab cetuximab and chemotherapy. Here, EGFR is linked to prostate carcinoma.